Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
Daxor (Nasdaq: DXR) has expanded its blood volume analysis (BVA) technology to two major hospitals within New Jersey's largest academic health care system. The hospitals are implementing on-site BVA analyzers to enable immediate access to precise blood volume measurements for critical care decisions.
The implementation aims to optimize fluid management, reduce hospital stays, and improve outcomes for heart failure and critical care patients. According to CEO Michael Feldschuh, the expansion demonstrates the effectiveness of their growth strategy, with dedicated resources in sales and marketing delivering meaningful results. The company expects to maintain this accelerated sales trajectory throughout 2025.
Daxor (Nasdaq: DXR) ha ampliato la sua tecnologia di analisi del volume ematico (BVA) in due importanti ospedali all'interno del più grande sistema sanitario accademico del New Jersey. Gli ospedali stanno implementando analizzatori BVA in loco per consentire un accesso immediato a misurazioni precise del volume ematico per decisioni critiche in ambito sanitario.
L'implementazione mira a ottimizzare la gestione dei fluidi, ridurre i tempi di degenza ospedaliera e migliorare i risultati per i pazienti con insufficienza cardiaca e in condizioni critiche. Secondo il CEO Michael Feldschuh, l'espansione dimostra l'efficacia della loro strategia di crescita, con risorse dedicate nelle vendite e nel marketing che portano a risultati significativi. L'azienda prevede di mantenere questa traiettoria di vendite accelerata fino al 2025.
Daxor (Nasdaq: DXR) ha ampliado su tecnología de análisis de volumen sanguíneo (BVA) en dos importantes hospitales dentro del sistema de atención médica académica más grande de Nueva Jersey. Los hospitales están implementando analizadores BVA en el lugar para permitir el acceso inmediato a mediciones precisas del volumen sanguíneo para decisiones críticas de atención médica.
La implementación tiene como objetivo optimizar la gestión de fluidos, reducir las estancias hospitalarias y mejorar los resultados para pacientes con insuficiencia cardíaca y en cuidados críticos. Según el CEO Michael Feldschuh, la expansión demuestra la efectividad de su estrategia de crecimiento, con recursos dedicados en ventas y marketing que generan resultados significativos. La empresa espera mantener esta trayectoria de ventas acelerada durante 2025.
Daxor (Nasdaq: DXR)는 뉴저지에서 가장 큰 학술 의료 시스템 내 두 개의 주요 병원에 혈액량 분석(BVA) 기술을 확장했습니다. 병원들은 현장 BVA 분석기를 구현하여 중환자 치료 결정을 위한 정확한 혈액량 측정에 즉각적으로 접근할 수 있도록 하고 있습니다.
이 구현은 체액 관리를 최적화하고, 병원에 머무는 시간을 줄이며, 심부전 및 중환자 치료 환자의 결과를 개선하는 것을 목표로 합니다. CEO 마이클 펠드슈에 따르면, 이번 확장은 그들의 성장 전략의 효과를 입증하며, 판매 및 마케팅에 전념하는 자원이 의미 있는 결과를 낳고 있습니다. 회사는 2025년까지 이러한 가속화된 판매 궤적을 유지할 것으로 예상하고 있습니다.
Daxor (Nasdaq: DXR) a étendu sa technologie d'analyse du volume sanguin (BVA) à deux grands hôpitaux au sein du plus grand système de santé académique du New Jersey. Les hôpitaux mettent en place des analyseurs BVA sur site pour permettre un accès immédiat à des mesures précises du volume sanguin pour des décisions critiques en matière de soins.
L'implémentation vise à optimiser la gestion des fluides, réduire les durées d'hospitalisation et améliorer les résultats pour les patients atteints d'insuffisance cardiaque et en soins critiques. Selon le PDG Michael Feldschuh, cette expansion démontre l'efficacité de leur stratégie de croissance, avec des ressources dédiées aux ventes et au marketing produisant des résultats significatifs. L'entreprise s'attend à maintenir cette trajectoire de ventes accélérée jusqu'en 2025.
Daxor (Nasdaq: DXR) hat seine Technologie zur Analyse des Blutvolumens (BVA) auf zwei große Krankenhäuser innerhalb des größten akademischen Gesundheitssystems in New Jersey ausgeweitet. Die Krankenhäuser implementieren vor Ort BVA-Analysatoren, um sofortigen Zugang zu präzisen Blutvolumenmessungen für kritische Entscheidungen in der Patientenversorgung zu ermöglichen.
Die Implementierung zielt darauf ab, das Flüssigkeitsmanagement zu optimieren, die Aufenthaltsdauer im Krankenhaus zu reduzieren und die Ergebnisse für Patienten mit Herzinsuffizienz und in kritischen Zuständen zu verbessern. Laut CEO Michael Feldschuh zeigt die Expansion die Effektivität ihrer Wachstumsstrategie, da engagierte Ressourcen im Vertrieb und Marketing bedeutende Ergebnisse liefern. Das Unternehmen erwartet, diesen beschleunigten Verkaufsverlauf bis 2025 aufrechtzuerhalten.
- Expansion into two major academic hospitals in New Jersey
- Expected sales growth trajectory throughout 2025
- Successful implementation of growth strategy
- None.
Insights
Daxor's expansion into two major New Jersey academic hospitals represents a meaningful commercial advancement for this small-cap medical technology company. With a market capitalization of just
This expansion is particularly notable as academic health systems typically have rigorous approval processes and can drive adoption across affiliated networks. The focus on heart failure and critical care applications targets high-value clinical areas where improved fluid management directly impacts length of stay and readmission rates—key metrics tied to hospital economics under value-based care models.
The company's statement about maintaining "accelerated sales trajectory" throughout 2025 suggests this isn't an isolated win but part of a broader commercial momentum. This aligns with healthcare systems' increasing focus on precision medicine approaches that can demonstrate measurable outcome improvements and cost reductions.
For investors, the key value proposition lies in Daxor's potential to establish a razor/razor-blade business model, where the initial analyzer placement generates follow-on consumable revenue with higher margins. Each new hospital implementation expands this recurring revenue base while simultaneously creating reference customers that can shorten future sales cycles.
The critical question remains how quickly Daxor can scale adoption across the approximately 6,000 hospitals in the US and whether they can maintain sufficient working capital to support an accelerated commercial expansion without additional financing.
Leading Academic Health System Adopts Daxor’s Innovative Blood Volume Measurement Capabilities at Two Key Facilities
Oak Ridge, TN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) at two major hospitals within New Jersey’s largest academic health care system. Based on current market momentum and expanding pipeline of opportunities, the Company expects to maintain this accelerated sales trajectory throughout 2025.
These two prestigious hospitals are in the process of implementing on-site BVA analyzers, enabling immediate access to precise blood volume measurements for critical care decisions. This investment allows their clinical teams to optimize fluid management, reduce hospital stays, and improve outcomes for heart failure and critical care patients.
"The continued expansion of our market footprint demonstrates the effectiveness of our growth strategy. The resources we have dedicated to strengthening our sales and marketing capabilities are delivering meaningful results," said Michael Feldschuh, CEO and President of Daxor. "This adoption by a leading healthcare system reflects the growing acknowledgment that our blood volume analysis technology plays a vital role in enhancing patient care outcomes."
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the latest expansion of Daxor's BVA technology announced in February 2025?
How will the BVA analyzers benefit patient care at the New Jersey hospitals?
What is DXR's sales outlook for 2025 following this expansion?
How does this expansion reflect on Daxor's growth strategy?
